Ustekinumab associated with flares of psoriatic arthritis

JAMA Dermatology

Volumn 149, Issue 12, 2013, Pages 1410-1413

  Stamell, Emily F ^a   Kutner, Allison ^a   Viola, Kate ^a   Cohen, Steven R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; METHOTREXATE; USTEKINUMAB;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MALE; MIDDLE AGED; PAIN ASSESSMENT; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS;

EID: 84892170359     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.5728     Document Type: Article

References (16)

1. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J AmAcad Dermatol. 2005;53(4):573.
2. Mease PJ, Gladman DD, Ritchlin CT, et al Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279-3289.
3. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264-2272.
4. Antoni C, Krueger GG, de Vlam K, et al; IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150- 1157.
5. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111(6):1053-1057.
6. Lee E, TrepicchioWL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125-130.
7. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998;25(8):1544-1552.
8. Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003;198(12):1951-1957.
9. Griffiths CE, Strober BE, van de Kerkhof P, et al ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118-128.
10. Leonardi CL, Kimball AB, Papp KA, et al; PHOENIX 1 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665- 1674.
11. Papp KA, Langley RG, Lebwohl M, et al; PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675- 1684.
12. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633- 640.
13. Kavanaugh A, Mclnnes AB, Gottlieb AB, et al. Ustekinumab in patients with active psoriatic arthritis: Results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Presented at the American College of Rheumatology Annual Meeting; November 11-14, 2012;Washington, DC.
14. Kavanaugh A, Mclnnes IB, Gottlieb AB, et al. Marked improvement of signs and symptoms by ustekinumab in patients with active psoriatic arthritis: week 52 results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Presented at the American College of Rheumatology Annual Meeting; November 11-14, 2012;Washington, DC.
15. Ritchlin CT, Gottlieb AB, Mclnnes IB, et al. Ustekinumab in active psoriatic arthritis including patients previously treated with ANTI-TNF agents: Results of a phase 3, multicenter, double-blind, placebo-controlled study. Presented at the American College of Rheumatology Annual Meeting; November 11-14, 2012;Washington, DC.
16. Stevenson ML, Markowitz O. Selection of therapies in patients with psoriasis and psoriatic arthritis. Psoriasis Forum. 2011;17:144-147.